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Abstract
Objective
The purpose of this study is to report our experience in using image-guided percutaneous
radiofrequency ablation (RFA) for the treatment of osteoid osteoma (OO) and the subsequent
duration of pain relief over a period of about six years (May 2013-March 2019; 70 months) at a
tertiary-care hospital in a developing nation.
Methods
A retrospective study was performed at the radiology department of Aga Khan University,
Karachi, Pakistan. All patients who had undergone image-guided percutaneous RFA for OO
between May 2013-March 2019 were included. All cases had been performed with CT-guidance
under general anesthesia, with an additional local anesthesia injection also administered to the
patients. A soloist needle had been used for RFA. The primary success rates, complications,
symptom-free intervals, and follow-ups were evaluated.
Results
In total, 15 patients (11 males, 4 females) of a mean age of 13.93 years (range: 5-25 years;
median age: 14.5 years) with OO underwent image-guided percutaneous RFA during a period of
70 months. Eleven lesions were located in the femur, three in the tibia, and one in the humerus.
The mean nidus size was 8.1 x 5.73 mm [range: (4.9-11.5) x (3.8-9.1) mm]. All patients were
successfully treated and experienced resolution of pain in 2.36 months (range: 1-4 months).
During the follow-up period (range: 3-40 months; mean: 13.85 months; median: nine months),
none of the patients experienced any relapse or persistent symptoms. No major complications
were reported.
Conclusion
Image-guided percutaneous RFA is a minimally invasive and safe treatment option with high
efficiency and a high rate of technical success for the treatment of OO. The risk of recurrence is
remote with all patients achieving independent recovery.
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Introduction
Osteoid osteoma (OO) is a relatively common, benign osteoblastic lesion that generally affects
children and adolescents [1]. It accounts for 10% of all benign bone tumors and has a male-to-
female predisposition ratio of 3:1 [2]. The most common and important clinical presentation
is pain during the night that is dramatically relieved by salicylates or other nonsteroidal anti-
inflammatory drugs (NSAIDs) [1, 3]. Other, less common, symptoms include growth
disturbances, bone deformities, painful scoliosis, joint swelling, and contractures. A physical
examination usually reveals localized tenderness without any signs of inflammatory disease. It
is postulated that the pain may be mediated by the release of prostaglandins, which results in
local vasodilatation [4, 5].
On plain films, OO is characterized by a circular or ovoid lucent nidus (usually less than 1.5 cm
in diameter) with a variable degree of surrounding reactive sclerotic cortical thickening [3]. If
sclerosis is extensive, it may interfere with the visualization of the radiolucent nidus on plain
radiographs. CT is the most sensitive and specific option in the diagnosis and localization of
OO, and thus the imaging modality of choice [2].
Different treatment strategies for OO have been implemented, including conservative medical
treatment, surgery, and percutaneous intervention. Conservative medical therapy is now
considered undesirable as it necessitates a prolonged period of therapy and long-term use of
anti-inflammatory drugs. Surgery is considered curative; however, some intramedullary and
subperiosteal lesions are difficult to localize intraoperatively as they may not demonstrate
significant sclerosis and the cortex overlying the site may appear normal during the procedure.
Surgery is also challenging for lesions smaller than 1 cm in diameter as it may lead to
significant unnecessary bone resection [6]. Therefore, CT-guided percutaneous RFA is an
effective technique that has been universally acknowledged as a minimally invasive, safe, and
cost-effective cure for OO. The purpose of this study is to describe our experience in using RFA
for the treatment of OO, its success rate, the duration of the pain relief it provided, and
potential complications encountered over a period of about six years (May 2013-March 2019;
70 months) at a tertiary-care hospital in a developing nation.
Materials And Methods
A retrospective study was performed at the radiology department of Aga Khan University,
Karachi, Pakistan, after gaining approval from the institutional ethical review committee (ERC).
All patients who underwent image-guided percutaneous RFA for OO between May 2013 to
March 2019 were included.
The clinical diagnosis of OO was based on reports of severe bone pain, pain during the night,
relief of pain after administration of NSAIDs, and on the basis of radiological features.
Patients who were offered image-guided percutaneous RFA for OO were also required to meet
specific imaging criteria, including the documentation of radiolucent nidus on plain film and
CT imaging, MRI, or any of the two (Figures 1, 2). In addition, bony sclerosis, cortical
thickening, and any periosteal reaction were also assessed. Patients who had undergone prior
surgery or intervention were excluded. Patients or parents/guardians (in cases involving
minors) were also informed regarding alternative treatment options. Informed consent was
obtained from each patient or their parents before the procedure. Pre-procedural management
included the assessment of complete blood cell count (CBC), blood clotting analyses (required
platelet count: >75,000/mL; international normalized ratio: <1.5 mL), and physical fitness test
to undergo general anesthesia. Patients were also examined for any evidence of local infection
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at the site of OO.
All cases were performed with CT-guidance under general anesthesia, with an additional local
anesthesia injection also administered to the patients. All cases were performed by a board-
certified interventional radiologist with at least five years of experience who was assisted by an
interventional radiology fellow. Contiguous CT (Aquilion 640, Toshiba Medical Systems, Tokyo,
Japan) scans with a section thickness of 1-5 mm were obtained to localize OO. Using the
images, we adjusted the position of the patient’s limb and marked the skin at the planned
access point. The skin was prepared and draped in the usual fashion. The lesion was accessed
with a 14-gauge bone-biopsy needle (Bonopty by AprioMed, Uppsala, Sweden). Using this
access made by the drill hole, the RF electrode (Soloist, Boston Scientific Corporation,
Marlborough, Massachusetts, US) was introduced into the nidus (Figures 1B, 2E). Lesion
ablation was subsequently performed using a standard protocol, which lasted between four-
eight minutes.
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FIGURE 1: Various imaging findings of a 24-year-old male with
an osteoid osteoma in the left tibia.
A) Unenhanced CT axial section showing osteoid osteoma in the tibia measuring 6.1 x 6 mm.
B) Soloist needle in the nidus (arrow).
C-F) Follow-up MRI after six months shows non-enhancing nidus (arrows), representing successful
ablation.
FIGURE 2: Various imaging findings of a six-year-old boy with
an osteoid osteoma along the medial margin of the right
femoral diaphysis.
A) Scanogram radiograph showing osteoid osteoma in the medial right femur with associated
cortical thickening (arrow).
B-D) Nidus (arrows) is measured and well-demarcated on unenhanced CT-extremity images with
surrounding cortical thickening.
E) Soloist needle (arrow) is within the nidus and used for radiofrequency ablation.
Each patient was assessed and examined before discharge for bleeding, swelling, skin burn,
neurovascular complications, and other procedure-related problems to assess the technical
success rate.
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Results
In total, 15 patients (11 males, 4 females) underwent image-guided percutaneous RFA for OO
during the period of 70 months (May 2013-March 2019). The mean age was 13.93 years (range:
5-25 years; median: 14.5 years). Pain during the night was the chief complaint from all patients,
followed by bone pain and tenderness (Figure 3).
FIGURE 3: Frequency of presenting complaints in patients with
osteoid osteoma.
A single lesion in a long bone was diagnosed and eventually treated in every patient. Out of
15 lesions, 11 were located in the femur, three in the tibia, and one in the humerus. The mean
size of the OO nidus was 8.1 x 5.73 mm [(4.9-11.5) x (3.8-9.1) mm], with minimal variation
between the maximum and the minimum dimensions of the nidus (Figure 4). The RFA
procedure was classified as radiologically successful when the RFA electrode was successfully
placed in the nidus, when there was pain relief, when there was no increase in the symptoms,
or in the absence of recurrence. The procedure was technically successful in all of the cases.
FIGURE 4: Relationship between the maximum and the
minimum sizes (in mm) of the osteoid osteoma nidus.
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The majority of the patients achieved complete pain relief within 10 days (1.5 weeks) after RFA
(mean: 1.5 weeks; range: 0.5-3.5 weeks; median and mode: 1.5 weeks). All patients were capable
of full weight-bearing after their procedure without any support. There was no major
restriction in physical activity for any of the patients after the procedure. No major
complications occurred during or after the procedure in any of the patient. However, a few
minor peri-procedural complications were reported (Figure 5). All patients demonstrated
subcutaneous edema after the procedure. A minimal cortical break was observed in seven
(46.7%) cases, secondary to needle manipulation. No major fracture was reported, and there
were no other procedure-related complications.
FIGURE 5: Frequency of peri-procedural local changes and
minor complications.
The mean follow-up duration was 13.85 months (range: 3-40 months; median: nine months).
The graphical relationship between the duration of symptom resolution and the follow-up
period is detailed individually below (Figure 6).
FIGURE 6: Relationship between the duration of symptom
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resolution and the follow-up period.
None of the patients experienced a persistence of symptoms or relapse during the follow-up
period, and no recurrence was reported. Preliminary results of this study were presented in the
33rd Annual Conference of the Radiological Society of Pakistan in Karachi (Abstract: Mustafa
Belal Hafeez Chaudhry, Basit Salam, Muhammad Azeemuddin, Raza Sayani, Tanveer ul
Haq. Computed Tomography Guided Percutaneous Radiofrequency Ablation in Treating
Osteoid Osteoma. Karachi, October 27-29, 2017). All the results are summarized below
(Table 1).
Study Group Demographics
Variables n (%)
Cases 15
Mean age 13.93 years (range: 5-25 years)
Males/females 7 (73%)/4 (27%)
Bone involved: femur/tibia/humerus 11 (73%)/3 (20%)/1 (7%)
Side involved: right/left 8 (53%)/7 (47%)
Duration of procedure 39.5 minutes (range: 25-50 minutes)
Symptom resolution (follow-up) 1.55 weeks (range: 0.5-3.5 weeks.)
Follow-up time (mean) 13.86 months (range: 3-44 months; median: nine months; mode: nine months)  
TABLE 1: Summarized results with different study variables.
Discussion
Percutaneous RFA for OO was first reported by Rosenthal et al. in 1992 [6], demonstrating that
image-guided percutaneous RFA is a safe and effective treatment for OO. In the present study,
clinically successful treatment was performed in 100% of the cases, which is comparable to the
success rates reported by many researchers, which range from 75% to 100%. It also compares
favorably with other techniques such as surgical resection and laser ablation [7-9].
It is debatable whether or not a cooling RFA probe system should be used. While some
researchers advocate its use to prevent osteonecrosis, others discourage it because of the
increased risk of post-procedural pain and complications such as wound infections and burns.
However, authentic and validated data in this regard is lacking [10-12]. We used a non-cooled
system in all our patients as that is the one commercially available in Pakistan. We did not
encounter any case of osteonecrosis in our patients who had follow-ups.
In cases of OO measuring over 1 cm in diameter, the use of two or more electrode positions is
often necessary [3]. Previous reports have also suggested that the odds of technically
unsuccessful percutaneous ablation increase if the nidus size is over 1 cm. We had three
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patients with a nidus size marginally greater than 1 cm (maximum: 1.15 cm). However, we were
able to achieve technical success in all the three patients with the use of a single electrode, and
without any residual or recurrent disease on follow-ups.
The major post-procedural complications reported in the literature include skin burns, skin and
fat necrosis, soft-tissue infections, vasomotor instability, tendinitis, and hematoma [7-9].
However, we did not encounter any of these major complications in our patients during or after
the procedure. These results are comparable to those of several previous reports of the
successful use of image-guided percutaneous RFA for the treatment of OO [7-9]. Periprocedural
soft- tissue edema was noted in all patients, which was relieved within three weeks. This has
been reported by Murat Cakar et al. and is thought to be a result of prostaglandin discharge
from OO during ablation [7]. All the cases of image-guided percutaneous RFA were performed
under general anesthesia, as it assists to achieve a stable condition and helps in adequate pain
control during the procedure. In addition, we also used local anesthesia in all patients for better
periprocedural pain management. We also did not experience any anesthesia-related
complications. Minor cortical breaks were observed during the RFA procedure in 46.7% of the
patients, which did not require any additional treatment. In contrast to image-guided
percutaneous RFA, percutaneous lesion resection leaves a bone defect that may be vulnerable
to fracture and, in some cases, may necessitate internal fixation and bone grafting, and may
also increase morbidity.
Caution is necessary when performing image-guided percutaneous RFA for spinal and hand OO
to avoid nerve injuries. Relative contraindication for RFA in such cases is the presence of OO
near a neurological structure within a distance of less than 5 mm, increasing the risk of spinal-
cord damage by hyperthermia-induced cytotoxicity [13]. Additionally, RFA may also cause
chondral damage due to thermal necrosis in juxta-articular lesions [14]. In our series, all lesions
were located in the long bones of the extremities, which helped to avoid neural structures and
major complications. We acquired immediate post-procedural CT sections of the target area to
evaluate for any immediate complication. However, it is not considered mandatory to routinely
perform CT after the procedure [3].
This study has a few limitations. One of the major limitations is the small sample size. It is
followed by the absence of the histological confirmation of OO in any of the cases we studied.
However, all of the patients did experience typical clinical symptoms of OO, and the diagnosis
was confirmed by typical imaging findings in each case. Hence, the histological verification was
unnecessary for the diagnosis of OO in all of the cases. Thirdly, there were no cases of spinal or
small bone OO, denying us the opportunity to demonstrate the technical success rate of RFA for
such lesions. Lastly, none of the lesions were large enough to utilize the dual-electrode
technique.
Conclusions
Image-guided RFA is a minimally invasive and safe option with high efficiency and a high rate
of technical success for the treatment of OO and should be considered the treatment of choice
in the current era. Our results also show that the risk of recurrence is remote with most patients
achieving independent recovery.
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